EQS-News
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets - Seite 3
Selected financial figures for the 2023 financial year
All amounts in kEUR |
2023 | 2022 |
Revenues | 9,183.5 | 11,275.9 |
Personnel expenses | -5,048.9 | -4,848.7 |
R&D expenses | -7,032.9 | -6,905.6 |
Operating result (EBIT) | -5,129.2 | -4,913.6 |
Loss for the year | -6,794.8 | -6,397.7 |
Basic earnings per share (in EUR) | -4.5 | -4.3 |
Equity | -10,136.4 | -4,157.1 |
Total assets | 14,611.7 | 22,286.6 |
Cash flow utilized by operating activities | -4,528.2 | -5,202.9 |
Cash and cash equivalents | 2,588.8 | 8,175.4 |
Total change in cash and cash equivalents | -5,586.5 | 2,373.2 |
Lesen Sie auch
Details of the 2023 full year results conference call:
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte